Similar Outcomes with Fresh and Frozen Corneal Allograft

KOLKATA, INDIA – SEPTEMBER 19: (EXCLUSIVE COVERAGE) Dr Roberto Pineda performs a corneal transplant as seen on a screen next to the operating theatre on the converted DC-10 Aircraft that charity Orbis uses as a flying opthalmic hospital at Kolkata airport on September 19, 2013 in Kolkata, India. During her solo visit to India the Countess is supporting the sight saving charity ORBIS. The Countess witnessed patients’ surgery and met patients’ during her tour of the plane. She also met medical volunteers from around the world who share their skills with local eye care workers to improve eye care in local communities. (Photo by Chris Jackson/Getty Images)
Researchers looked at 10 years of data showing KPro device retention, visual acuity, and complications.

The following article is a part of conference coverage from the American Academy of Ophthalmology 2020, being held virtually from November 13 to 15, 2020. The team at Ophthalmology Advisor will be reporting on the latest news and research conducted by leading experts in ophthalmology. Check back for more from the AAO 2020.

Patients implanted with the Boston keratoprosthesis type 1 (KPro) implantation experience similar device retention, visual acuity, and complications whether using a fresh or frozen allograft, say investigators, after 10 years of research.

The team looked at 19 eyes of 19 patients. The group implanted with a fresh corneal allograft consisted of 11 patients, while the group given the frozen ones had 8 participants. All patients were implanted with the devices by a single surgeon at a single center between October 2008 to March 2010.

A decade later, the fresh group saw 91% device retention, and the frozen group saw 75% device retention. The mean best-corrected visual acuity for patients who had undergone the procedure increased from counting fingers to 20/300 in the fresh group and 20/125 in the frozen group. The incidence of complications per patient was nearly identical in this study with the fresh group seeing 2.36 complications per patient and the frozen group seeing 2.37. 

The researchers noted no statistically significant differences between groups for any of these outcome measures (P >.05 for all analyses).

Visit Ophthalmology Advisor’s conference section for complete coverage of AAO 2020.



Sabeti S, Daoud R, Robert M, Harissi-Dagher M. RCT of Fresh vs. Frozen Corneal Allograft Carriers in Boston Keratoprosthesis Type 1 Surgery: Ten-Year Outcomes. Presented at: American Academy of Ophthalmology 2020 Annual Meeting; November 13-15, 2020. Abstract PO112.